Skip to content
OWP Pharmaceuticals

Menu

OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Document loads below this notification.

Quick Links

About Us

Our Purpose

Our People

Leadership Team

Board of Directors

FAQs

Products

Subvenite Starter Kits
(Lamotrigine)

Lamotrigine Starter Kits
(Lamotrigine)

Roweepra IR
(Levetiracetam)

Our Future

Pipeline

News

Press Releases

Events

Connect

Careers

Contact Us

About OWP

Our focus is to support providers and patients in the US with beneficial medications, and use profits to provide resources for those living with neurological disorders in under-resourced areas of the world… Learn More

Contact Us

OWP Pharmaceuticals

© 2023 OWP Pharmaceuticals, Inc. All Rights Reserved. The OWP Pharmaceuticals logo, ROW Global logo, WorldPrint iconography, Heart Venn Diagram image, phrase “One World. One Standard.”, phrase “The Pharmaceutical Social Enterprise”, and phrase “Epilepsy is a global problem that deserves a global solution.” are all registered service marks of OWP Pharmaceuticals, Inc. Website by 4FrontDesign.

  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
OWP Pharmaceuticals

© 2023 OWP Pharmaceuticals, Inc. All Rights Reserved. The OWP Pharmaceuticals logo, ROW Global logo, WorldPrint iconography, Heart Venn Diagram image, phrase “One World. One Standard.”, phrase “The Pharmaceutical Social Enterprise”, and phrase “Epilepsy is a global problem that deserves a global solution.” are all registered service marks of OWP Pharmaceuticals, Inc. Website by 4FrontDesign.

  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
OWP Pharmaceuticals
CloseMenu

About Us

Our Purpose
Our People
Leadership Team
Board of Directors
FAQs

Products

Subvenite Starter Kits
Lamotrigine Starter Kits​
Roweepra IR​

Our Future

Pipeline

News

Press Releases
Events

Connect

Careers
Contact Us

© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.

  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer

© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.

  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer

© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.

  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer
  • Cookies
  • Terms of Use
  • Privacy
  • Social Media Policy
  • Disclaimer